ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL.

The trial is enrolling adult women with recurrent ovarian cancer after at least two previous therapies. Credit: Jo Panuwat D / Shutterstock.com. (Jo Panuwat D / Shutterstock.com.) Anixa Biosciences ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European ...

Perovskite silicon tandem solar cell efficiency now has an accredited European calibration pathway: Germany’s ISFH CalTec ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Scientists say they have built a cell from scratch for the first time that feeds, grows and replicates like a natural cell, a ...

SHANGHAI, NANJING, and PLEASANTON, Calif., June 18, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, ...

Fat mass and obesity-associated protein (FTO), an epitranscriptomic regulator, has been implicated in cancer progression and immune regulation but the therapeutic relevance in pancreatic cancer is ...

DZNE researchers have uncovered a mechanism that determines why a neuron usually forms a single, long extension called an ...

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical ...

Forecasters say some of the thunderstorm cells could bring frequent lightning and strong gusty winds that could trigger more ...